Skip to main content
SpringerLink
Log in

Pharmakologische Therapie der erektilen Dysfunktion

  • Chapter
Pharmakotherapie in der Urologie

  • 59 Accesses

Zusammenfassung

Auf Grund der intensivierten Forschungsanstrengungen zum Grundlagenwissen [1–3] und zu dem klinischen Anwendungen [4, 5], die innerhalb der letzten Jahrzehnte auf dem Gebiet des normalen und gestörten Erektionsmechanismus unternommen worden sind, steht Arzt und Patient ein breit gefächertes, wenn auch noch keineswegs zufriedenstellendes Angebot von Behandlungsmöglichkeiten gegenüber. Diese breite Palette von therapeutischen Optionen erlaubt in vielen Fällen die Möglichkeit eines weitgehenden Eingehens auf Wünsche und individuelle Gegebenheiten des Patienten. In Anbetracht der Tatsache, daß eine erektile Dysfunktion oft ein multifaktorielles Geschehen darstellt [4], erlaubt dieses Armentarium aber auch, sich die Kompensationsfähigkeit des Organismus zu Nutze zu machen: So kann, zumindest theoretisch, durch eine geeignete oral einzunehmende Substanz mit ausreichend selektiv relaxierender Wirkung auf die glatte Muskulatur des Schwellkörpers eine arterielle Einflußstörung oder eine cavernös-venöse Insuffizienz wettgemacht werden [6]. Oder es kann durch die erhöhte zentrale Erregung Erektions-induzierender Zentren mittels oraler alpha2-Rezeptorenblocker eine Erektionsschwäche, die durch Versagensangst oder Streß verursacht ist, behoben werden [7]. In gleicher Weise kann eine psychologische Beratung oder eine Sexualtherapie einen „milden” organischen Faktor kompensieren [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Rampin O, Bernabe J, Guilano F (1997) Spinal control of penile erection. World J Urol 15: 2–13

    Article  PubMed  CAS  Google Scholar 

  2. Andersson KE, Stief CG (1997) Neurotransmission and the contraction and relaxation of penile erectile tissues. World J Urol 15: 14–20

    Article  PubMed  CAS  Google Scholar 

  3. Shabsigh R (1997) The effects of testosterone on the cavernous tissue and erectile function. World J Urol 15: 21–26

    Article  PubMed  CAS  Google Scholar 

  4. Hartmann U (1997) Pyschological subtypes of erectile dysfunction. World J Urol 15: 256–264

    Article  Google Scholar 

  5. Truss MC, Becker AJ, Schultheiss D, Jonas U (1997) Intracavernous Pharmacotherapy. World J Uro1,15(1): 71–77

    Article  CAS  Google Scholar 

  6. Boolell M, Allen MJ, Ballard SA (1996) Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. IJIR 8: 47–52

    CAS  Google Scholar 

  7. Vogt HJ, Brandl P, Kockott G, Schmitz JR, Wiegand MH, Schadrack J, Gierend M (1997) Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res 9(3): 155–161

    Article  PubMed  CAS  Google Scholar 

  8. Heaton JP, Adams, MA, Morales A, Brock G, Shabsigh R, Lue T F (1996) Apomorphine SL is effective in the treatment of non-organic erectile dysfunction. Int. J. Impotence Res. 8: 115

    Google Scholar 

  9. Padma-Nathan H, Auerbach S, Lewis R, Lewand M, Perdock R (1999) Efficacy and sefety of Apomorphine SL vs placebo for male erectile dysfunction. J Urol 161: 214 A

    Article  Google Scholar 

  10. Padma-Nathan H, Hellstrom W, Kaiser FE et al. (1997) Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 336: 1

    Article  PubMed  CAS  Google Scholar 

  11. Porst H, Derouet H, Idzikowski M et al. (1996) Oral phentolamin in erectile dysfunction. Int J Impotence Res 8: 117

    Google Scholar 

  12. Sikora R, Sohn M, Bosshardt R, Jakse G: Trazodone in diagnosis and therapy of erectile dysfunction. Int J Impotence Res 4: A100

    Google Scholar 

  13. Spivack AP, Peterson CA, Cowley C et al. (1997) Long-term safety profile of transurethral alprostadil for the treatment of erectile dysfunction. J Urol 157: 203 A

    Article  Google Scholar 

  14. Virag R (1982) Intracavernous injection of papaverine for erectile failure. Letter to the editor. Lancet 2: 938

    Article  PubMed  CAS  Google Scholar 

  15. Kirkeby HJ, Johannesen NL(1989) Pharmacologically induced prolonged erections produced by papaverine. Follow-up of injection therapy, Scand J Urol Nephrol Suppl, 125: 97–100

    PubMed  CAS  Google Scholar 

  16. Jantos C, Krause W, Kauss E, Weidner W (1988) Long-term experiences with autoinjection therapy of papaverine in erectile dysfunction. Urologe A, 27: 18–21

    PubMed  CAS  Google Scholar 

  17. Juenemann KP, Alken P (1989) Pharmacotherapy of erectile dysfunction: a review. Int J Impotence Res 1: 71–93

    Google Scholar 

  18. Wetterauer U (1991) Intracavernous pharmacotherapy for erectile dysfunction. In: Jonas U, Thon WF, Stief CG (eds) Erectile dysfunction. Springer, Berlin Heidelberg New York Tokyo, p 221–235

    Chapter  Google Scholar 

  19. Ishii N, Watanabe H, Irisawa C, Kikushi Y (1986) Therapeutic trial with prostaglandin El for organic impotence. Second World Meeting on Impotence 1986, Prague

    Google Scholar 

  20. Hwang TI, Yang CR, Wang SJ, Chang CL, Tzai TS, Chang CH, Wu HC (1989) Impotence evaluated by the use of prostaglandin El. J Urol 141: 1357–1359

    PubMed  CAS  Google Scholar 

  21. Porst H (1988) Value of prostaglandin El in the diagnosis of erectile dysfunction in comparison with papaverine and papaverine/phentolamine in 61 patients with erectile dysfunction. Urologe A 27: 22–26

    PubMed  CAS  Google Scholar 

  22. Stackl W, Hasun R, Marberger M (1988) Intracavernous injection of prostaglandin El in impotent men. J Urol 140: 66–68

    PubMed  CAS  Google Scholar 

  23. Waldhauser M, Schramek P (1988) Efficiency and side effects of prostaglandin El in the treatment of erectile dysfunction. J Urol 140: 525–527

    PubMed  CAS  Google Scholar 

  24. Porst H, Buvat J, Hauri D et al. (1994) Self-injection therapy with prostaglandin El — Longterm results of an international multicenter study accoeding to the GCP-standard. Int J Impotence Res 6: D108

    Google Scholar 

  25. Linet OI, Neff LL (1994) Intracavernous prostaglandin El in erectile dysfunction. Clin Investig 72: 139–149

    Article  PubMed  CAS  Google Scholar 

  26. Bennett AH, Carpenter AJ, Barada JH (1991) An improved vasoactive drug combination for pharmacological erection program. J Urol 146: 1564–1568

    PubMed  CAS  Google Scholar 

  27. Collins J, Thijssen A (1993) Experience with intracorporal prostaglandin El, papaverine and phentolamine in patients with erectile dysfunction. J Urol 149: 345 A

    Google Scholar 

  28. Dilworth JP, Lewis RW (1991) The use of multicomponent injection agents in the diagnosis and treatment of impotence. J Urol 145: 232 A

    Google Scholar 

  29. Goldstein I, Borges FD, Fitch WP et al. (1990) Rescuing the failed papaverine/phentolamine erection: a proposed synergistic action of papaverine, phentolamine and prostaglandin El. 5J Urol 143: 304 A

    Google Scholar 

  30. Richter S, Nissenkorn I (1994) Three years, 200 patients, 10,000 intracavernous self-injections with a triple-drug combination for the treatment of erectile dysfunction. Int J Impotence Res 6: D133

    Google Scholar 

  31. Montorsi F, Guazzoni G, Bergamaschi F, Dodesini A, Rigatti P, Pizzini G, Miani A (1993) Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence. Urology 42: 554–558

    Article  PubMed  CAS  Google Scholar 

  32. Stief CG, Benard F, Bosch R, Aboseif S, Wetterauer U, Lue TF, Tanagho EA (1993) Calcitonin gene-related peptide: possibly neurotransmitter contributes to penile erection in monkeys. Urology 41: 397–401

    Article  PubMed  CAS  Google Scholar 

  33. Truss MC, Becker AJ, Thon WF, Kuczyk M, Djamilian MH, C. Stief G, Jonas U (1994) Intracavernous calcitonin gene-related peptide plus prostaglandin E 1: possible alternative to penile implants in selected patients. Eur Urol 26: 40–45

    PubMed  CAS  Google Scholar 

  34. Truss MC, Becker AJ, Djamilian MH, Stief CG, Jonas U (1994) The role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology 44(4): 553–556

    Article  PubMed  CAS  Google Scholar 

  35. Buvat J, Lemaire A, Buvat HM, Marcolin G (1989) Safety of intracavernous injections using an alpha-blocking agent. J Urol 141: 1364–1367

    PubMed  CAS  Google Scholar 

  36. Andersson KE, Holmquist F (1994) Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J Urol 12: 149–261

    Google Scholar 

  37. Wagner G, Gerstenberg T (1988) Vasoactive intestinal polypeptide facilitates normal erection. Third Biennial World Meeting on Impotence 1988, Boston, p 146

    Google Scholar 

  38. Kiely EA, Bloom SR, Williams G (1989) Penile response to intracavernosal VIP alone and in combination with other vasoactive agents. Br J Urol 64: 191

    Article  PubMed  CAS  Google Scholar 

  39. Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J (1992) Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure J Urol 147: 1277–1279

    CAS  Google Scholar 

  40. McMahon CG (1996) A pilot study of the role of intracavernous Injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impotence Res 8(4): 233–236

    CAS  Google Scholar 

  41. Mulhall JP, Daller M, Traish AM et al. (1997) Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol 158: 1572–1579

    Article  Google Scholar 

  42. Giraldi A, Wagner G (1990) Effect of pinacidil upon penile erectile tissue in vitro and in vivo. Pharmacol Toxicol 67: 235–238

    Article  PubMed  CAS  Google Scholar 

  43. Hellstrom WJ, Wang GR, Kadowitz PJ, Domer FR (1992) Potassium channel agonists cause penile erection in cats. Int J Impotence Res 4: 35–43

    Google Scholar 

  44. Feenstra J, van Drie-Pierik RJ, Lacle CF, Stricker BH: Acute myocardial infarction associated with sildenafil. Lancet 352: 957–958, 1998

    Article  PubMed  CAS  Google Scholar 

  45. Nelson RP, Barada JH, Costabile RA, Labasky RF, Lewis RW, Melman A, Spivack AP, Gesundheit N (1999) Does renewed sexual activity increase cardiac morbidity? Meta-analysis of the experience with MUSE’. J Urol 161(4): 215

    Article  Google Scholar 

  46. Hackett G, Gingell C (1999) Long term safety and efficacy after 2 years of Viagra. J Urol 161(4): 214

    Article  Google Scholar 

  47. Virag R (1999) Indications and early results of Sildenafil in erectile dysfunction. Urology 54: 1073–1077

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. J. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Truss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. G. Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Michael C. Truss , Christian G. Stief , Stefan Machtens  & Udo Jonas (Direktor), ,  &  (Direktor)

  2. Zentrum Anästhesiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Till Wagner

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Becker, A.J., Truss, M., Stief, C.G. (2002). Pharmakologische Therapie der erektilen Dysfunktion. In: Truss, M.C., Stief, C.G., Machtens, S., Jonas, U., Wagner, T. (eds) Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09273-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09273-6_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41519-0

  • Online ISBN: 978-3-662-09273-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation